Related Experiment Video
Updated: Jun 3, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines
1GlaxoSmithKline Biologicals, Rue de l'Institut 89, 1330 Rixensart, Belgium. jan.poolman@gskbio.com
Abstract:
Hyporesponsiveness (immune tolerance) follows vaccination with meningococcal polysaccharide and many pneumococcal polysaccharide serotypes. Hyporesponsiveness after Haemophilus influenzae type b polysaccharide vaccination has not been directly observed, but may follow exposure during disease in some individuals. Use of currently licensed conjugate vaccines has not been associated with hyporesponsiveness to date, with the possible exception of pneumococcal serotype 3. Introduction of polysaccharide vaccines anywhere into a conjugate vaccination schedule may result in reduced immune responses on subsequent exposure. This review of vaccine-induced hyporesponsiveness and its potential clinical implications considers recent evidence suggesting that hyporesponsiveness may occur for specific components of combined conjugate vaccines, such as pneumococcal serotype 3. These data have implications for the development of new multivalent vaccines.
More Related Videos
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions
Hypersensitivity Reactions: Immune-Complex Reactions
Vaccinations
Drug Toxicity: Allergic Reactions
Hypersensitivity Reactions: Cytolytic Reactions

